Results 141 to 150 of about 19,663 (194)

Utilization of machine learning models and grey wolf optimization method in estimation of pharmaceutical solubility in supercritical CO₂. [PDF]

Front Chem
Abu-Hamdeh NH, Aljinaidi AA, Khoshaim AB.   +2 more
europepmc   +1 more source

Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases. [PDF]

Front Oncol
Yang H, Da Y, Shen G, Sun QY, Yao ZY, Zhou YJ.   +5 more
europepmc   +1 more source

Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping. [PDF]

Discov Oncol
Yang J, Weng CD, Wang HM, Su JW, Tan QQ, Lin XC, Fang MM, Mao ZJ, Chen HJ, Li H, Lin G, Wu YL, Guo Y, Yang JJ.   +13 more
europepmc   +1 more source

<i>EZR-ROS1</i>-rearranged lung adenocarcinoma presenting as diffuse cystic lung disease mimicking lymphangioleiomyomatosis: a case report. [PDF]

Transl Lung Cancer Res
You Z, Bi W, Cao H, Wang Y, Shi C, Zhou Y, Li L.   +6 more
europepmc   +1 more source

Response to crizotinib treatment for ROS1 p.H1999N mutation and secondary EGFR p.V774M mutation after drug resistance: a Case Report. [PDF]

Front Pharmacol
He Y, Tang Y, Yu R, Liu Y.
europepmc   +1 more source

Tolerance and Efficacy of Targeted Therapies After Immunotherapy for Advanced Non-Small Cell Lung Cancers Harboring Oncogenic Alterations: The GFPC-TOXIMAD Study. [PDF]

Curr Oncol
Pierret T, Auliac JB, Ricordel C, Daniel C, Nguyen J, Guisier F, Swalduz A, Curcio H, Desage AL, Bigay-Game L, Huchot E, Falchero L, Doubre H, Bylicki O, Chouaïd C, Greillier L.   +15 more
europepmc   +1 more source

Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer. [PDF]

Respir Res
Lin J, Xia G, Wu Y, Chen L, Zhang Y, Ma Y, Yin JC, Zhang Z, Pan X.   +8 more
europepmc   +1 more source

Advanced ALK-EML4 fusion-positive non-small cell lung cancer with intraspinal metastases: a case report. [PDF]

Front Oncol
Lang J, Guo B, Han Q, Xiong Z.
europepmc   +1 more source

Case Report: Recurrent uterine inflammatory myofibroblastic tumor harboring <i>IGFBP5-ALK</i> fusion with sustained response to iruplinalkib. [PDF]

Front Oncol
Zhao K, Hu M, Yang R, Huang Y.
europepmc   +1 more source

Anaplastic Lymphoma Kinase Positive Aggressive Adult Lung Primary Inflammatory Myofibroblastoma Tumor: A Case and Literature Review. [PDF]

Pharmgenomics Pers Med
Xu P, Lu S.
europepmc   +1 more source